Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT
L Li(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Ioannis Politikos(Beth Israel Deaconess Medical Center), Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Jerome Ritz(Dana-Farber Cancer Institute), Victoria Petkova(Beth Israel Deaconess Medical Center), H T Kim(Dana-Farber Cancer Institute), Corey Cutler(Harvard University), Karen K. Ballen(University of Virginia Health System), Joseph H. Antin(Dana-Farber Cancer Institute), Robert J. Soiffer(Dana-Farber Cancer Institute), Sarah Nikiforow(Otsuka (Japan)), Sean M. McDonough(Harvard University), Anoma Nellore(NYU Langone Health)
Cited by 29
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k